Preliminary Revenue of $1.1 Million is the Highest Quarterly Revenue in the Company's History

SURPRISE, Ariz., Oct. 15, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in rodent birth control and sustainable rodent population management, today announced preliminary revenue results for the third quarter of 2026. The Company plans to release its definitive third quarter financial results the week of November 9, 2026.

Preliminary third quarter 2026 revenue was approximately $1.1 million, representing approximately 40% growth compared with the second quarter of 2026 and approximately 55% growth compared with the third quarter of 2025. It was also the Company's first quarter at or above the $1 million revenue threshold, a key milestone.

The Company expects its definitive third quarter financial results to reflect continued momentum in e-commerce, including higher subscription revenue, which is expanding the recurring component of SenesTech's revenue base, as well as increasing traction in B2B.

"Our preliminary third quarter revenue marks an important milestone for SenesTech, reaching the $1 million threshold for the first time and setting a second consecutive quarterly record," said Michael Edell, Chief Executive Officer of SenesTech. "This is another quarter demonstrating progress on the plans and strategies we have previously announced, and our full third quarter financial results are expected to reflect that progress across the commercial model we have been building. E-commerce continues to scale as a controllable, data-driven acquisition engine, our vertical-focused B2B organization is gaining traction, and higher subscription revenue is expanding our recurring revenue base and improving the quality and visibility of revenue."

"We still have work to do, but we believe this is a clear indication that we are on the right path. We continue to lay the foundation for a much larger company in the future by working to expand e-commerce and B2B significantly in a cost-effective manner. With many of the investments and transition costs incurred earlier in the year increasingly behind us, coupled with strong revenue growth and improved unit economics, we expect continued, improved metrics going forward," Edell concluded.

The preliminary third quarter 2026 revenue presented in this release is unaudited, preliminary and subject to adjustment, and remains subject to completion of the Company's quarter-end closing procedures.

About SenesTech

SenesTech is the leader in rodent birth control and sustainable rodent population management, with a mission to support a healthier environment through the responsible management of animal pest populations. The Company's Evolve® and ContraPest® fertility control solutions, along with its assessment and monitoring services, target reproduction to help reduce rodent populations. SenesTech serves consumer and professional markets with proven approaches that can be used independently or as part of an integrated pest management (IPM) program.

For more information, visit https://senestech.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include statements regarding the Company's expected third quarter 2026 revenue, anticipated momentum in e-commerce and increasing traction in B2B, expected progress across the Company's commercial model, and anticipated continued, improved metrics going forward. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "should," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include the risk that the Company may not realize the benefits expected from its e-commerce, B2B and subscription strategies, or be successful in commercialization of its products, realize sufficient market acceptance of its products, or capitalize on market opportunities and accelerate growth; the risks of establishing an entirely new product category, including the time, expense and uncertainty of building market awareness and customer acceptance; the risk that the Company may not be able to build and scale a professional B2B sales organization and to execute a vertical-market strategy; risks related to the Company's financial performance, including its ability to fund operations and potentially using cash at times and in ways other than as planned; and risks related to regulatory approval and regulation of the Company's products. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission, including under "Risk Factors" in its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2025, and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by law, SenesTech undertakes no obligation to update or revise any forward-looking statement.

Contacts:

Investor: Robert Blum, Lytham Partners, LLC, 602-889-9700, [email protected]

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.

Share this article

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use

In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use

Across both types of inflammatory bowel disease, including patients with prior biologic failure, achieving comprehensive disease control or corticosteroid-free deep remission was associated with improved patient-reported outcomes

INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- New data analyses from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease treated with Omvoh (mirikizumab-mrkz) achieved multiple treatment goals simultaneously at one year, as measured by comprehensive disease control in UC and corticosteroid-free deep remission in Crohn's disease. These multidimensional outcomes were observed even in patients with prior biologic failure, a population often facing greater treatment challenges. More than one-third of patients in the UC analysis and nearly half of patients in the Crohn's disease analysis had previously experienced biologic treatment failure. Furthermore, patients who achieved these endpoints were more likely to also achieve remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), a validated patient-reported measure of health-related quality of life. Together, these findings reflect an evolution of treatment goals in inflammatory bowel disease (IBD), looking across symptoms, inflammation and impact of disease on daily life to support a more holistic, patient-centered approach that goes beyond clinical remission. These post-hoc data from the LUCENT and VIVID programs will be presented at United European Gastroenterology (UEG) Week 2026.1,2

"Treatment in inflammatory bowel disease is often measured one endpoint at a time. These new data show that patients treated with Omvoh achieved multiple treatment goals simultaneously at one year, including those with prior biologic failure, and were more likely to report better quality of life," said Anabela Cardoso, senior vice president, Lilly Immunology Medical Affairs. "These findings reinforce the impact that Omvoh can have for people living with ulcerative colitis and Crohn's disease and show that a higher bar for disease control is achievable."

A comprehensive approach to IBD management considers multiple dimensions of disease, including the symptoms patients experience, what clinicians can objectively measure and how disease affects daily life.3-4 In previously published real-world studies, improvements across multiple dimensions of disease have been associated with a lower risk of flares, steroid use, hospitalization and surgery over time.4-7

"Inflammatory bowel disease is complex, and understanding treatment impact requires a broader view than any single endpoint can provide. These endpoints reflect a meaningful shift in how we define treatment success," said Stefan Schreiber, M.D., University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel. "Across the LUCENT and VIVID programs, Omvoh-treated patients achieved multidimensional treatment outcomes, including comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease. Importantly, these outcomes were also observed in patients with prior biologic failure."

Comprehensive disease control with Omvoh in ulcerative colitis

Comprehensive disease control is a novel composite outcome, informed by an international expert consensus3, that combines clinical remission*, no corticosteroid use for at least 12 weeks before Week 52, histologic remission† and fecal calprotectin ≤250 μg/g. Omvoh is the first IL-23p19 inhibitor evaluated for comprehensive disease control in UC, reflecting an evolving approach to treatment goals that goes beyond individual measures of disease activity for people living with UC. 

Comprehensive disease control was evaluated in a post hoc analysis at one year in patients with UC who responded to Omvoh at Week 12 in the LUCENT-1 induction study and were re-randomized in LUCENT-2 to continue Omvoh or receive placebo. More than one-third of patients (35.3%) had previously experienced biologic treatment failure.

At one year:1

- 27.7% of patients treated with Omvoh achieved comprehensive disease control compared with 14% receiving placebo.‡

- Among patients with prior biologic failure, 23.4% of those treated with Omvoh achieved comprehensive disease control compared with 9.4% receiving placebo.‡

- Among Omvoh-treated patients, 91.1% of those who achieved comprehensive disease control also achieved IBDQ remission§, compared with 65.2% of those who did not achieve comprehensive disease control.

- Omvoh-treated patients who achieved comprehensive disease control were also more likely to report no to minimal bowel urgency (bowel urgency remission) and greater improvements in work productivity than those who did not achieve comprehensive disease control.∥

Corticosteroid-free deep remission with Omvoh in Crohn's disease

Corticosteroid-free deep remission was evaluated in a post hoc analysis at one year in patients with Crohn's disease in VIVID-1. Nearly half of patients (48.6%) had previously experienced biologic treatment failure. Corticosteroid-free deep remission is a composite outcome that combines clinical remission (as measured by the Crohn's Disease Activity Index), endoscopic remission and no corticosteroid use for at least 12 weeks before Week 52.¶

At one year:2

- 20.4% of patients receiving Omvoh achieved corticosteroid-free deep remission compared with 2% receiving placebo.#

- Among patients with prior biologic failure, 15.7% of those treated with Omvoh achieved corticosteroid-free deep remission compared with none of those receiving placebo.#

- Among Omvoh-treated patients, 88.1% of those who achieved corticosteroid-free deep remission also achieved IBDQ remission§, compared with 51% of those who did not achieve corticosteroid-free deep remission.

The safety findings observed in the Phase 3 LUCENT and VIVID clinical trial programs have been reported previously. The most common adverse reactions associated with Omvoh treatment in LUCENT-1 and -2 (reported in at least 2% of subjects at a higher frequency than placebo) were upper respiratory tract infections, injection site reactions, arthralgia, rash, headache and herpes viral infection. In VIVID-1, the most common adverse reactions associated with Omvoh treatment (reported in at least 5% of subjects at a higher frequency than placebo) were upper respiratory tract infections, injection site reactions, headache, arthralgia and elevated liver tests.8

Omvoh has received regulatory approvals for the treatment of moderately to severely active UC and moderately to severely active Crohn's disease in adults and has been approved in 47 countries. Omvoh is also approved as a single-injection maintenance regimen for adults with UC in several countries around the world, including the U.S., EU, Canada and Japan.

Lilly continues to advance the standard of care in gastroenterology through the next wave of immunology innovation, including combination approaches, novel mechanisms and the potential of incretins. Lilly is pursuing combination studies of mirikizumab aimed at delivering breakthrough induction efficacy while maintaining long-term remission and safety. These include studies in UC with eltrekibart (NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with zotemtegrast (NCT07186101), an oral α4β7 integrin inhibitor. In Crohn's disease, Lilly is studying mirikizumab in combination with an FXR agonist (NCT07483099). The COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials are investigating the concomitant use of mirikizumab and an incretin-based therapy in adults with UC or Crohn's disease and obesity or overweight with at least one additional weight-related comorbid condition. In addition, trials of mirikizumab in pediatric patients are ongoing, including a long-term extension study in UC and Crohn's disease (NCT04844606) and an ongoing Phase 3 study in pediatric Crohn's disease (NCT05509777).

About the LUCENT Clinical Trial Program

Omvoh was studied in two Phase 3 clinical trials which evaluated the efficacy and safety of Omvoh in adults with moderately to severely active UC, in both biologic-naïve patients and those who had previously failed a biologic or Janus kinase inhibitor (JAKi).

The randomized, double-blind, placebo-controlled LUCENT-1 (induction) study included patients with an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, biologic therapy, or JAKi, and LUCENT-2 (maintenance) evaluated continued treatment versus placebo in patients who achieved a clinical response to Omvoh in LUCENT-1.

About the VIVID Clinical Trial Program

VIVID-1 was a Phase 3 randomized, double-blind, placebo-controlled 52-week study in adults with moderately to severely active Crohn's disease. Patients randomized to Omvoh received Omvoh 900 mg by intravenous (IV) infusion at Week 0, Week 4 and Week 8, followed by a maintenance dose of 300 mg by subcutaneous injection (SC) at Week 12 and then every four weeks (Q4W) for 40 weeks.

About Omvoh

Omvoh (mirikizumab-mrkz) is an interleukin-23p19 (IL-23p19) antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of inflammatory bowel disease.

FRANKFURT, Germany and HOUSTON, Oct. 15, 2026 /PRNewswire/ -- Creality today launches two new additions to its Ender-3 series, Ender-3 V3 Mega, a large-format 3D printer designed for small-batch production and TPU printing, and Ender-3 V3 Neo, a compact 3D printer built for first-time and entry-level buyers. Starting October 15, both printers are available to order through Creality's official stores at early-bird prices of $669 for the Mega Combo and $329 for the Neo Combo.

Nine years after its first launch, the Ender-3 series continues to evolve for creators with different levels of experience and varying fabrication needs. With more than 4 million units shipped, the series has inspired makers around the world. For many users, Ender-3 has been part of their creative journey, from their first prints to projects that push the boundaries of creativity. The two new members continue that journey, with Mega supporting batch production and Neo offering an accessible desktop option for everyday creative printing.

Large-Format Printing & Flexible TPU Production

With a 420 × 420 × 420 mm build volume, the Ender-3 V3 Mega enables users to print large models in one piece, minimizing the need for model splitting, assembly work and visible seams. In batch production, multiple objects can be arranged on a single build plate, helping print farms or design studios complete more jobs in fewer print runs. The mega size is suitable for applications such as large cosplay props, furniture components and batches of functional prototypes, where build capacity and production efficiency matter.

Beyond its build volume, Mega is designed for flexible 85A–95A TPU printing, powered by the optimized Sprite 2 extruder and printing algorithms. It supports producing protective covers, flexible connectors and other functional parts that require elasticity.

Note: TPU printing supports direct feeding from spool only and is not compatible with the automatic relay module or the CFS Nano.

Multicolor Printing with CFS Nano

Mega and Neo feature automatic filament relay, which switches to the backup filament when the current spool runs out, reducing interruptions during long prints. The Combo version supports four-color printing when paired with the CFS Nano, which can read material types and colors from compatible Creality RFID filaments. The CFS Nano also monitors remaining filaments and alerts users when they are running low.

With a high-rigidity metal frame, Mega maintains stable printing performance while delivering large outputs. Dual Z motors and vibration compensation help reduce ringing and layer shifts, and dual Y motors drive the large build plate smoothly at speeds up to 500 mm/s.

Easy Setup and Printing for New Makers

Built for everyday creative projects, the compact Ender-3 V3 Neo offers a 220 × 220 × 220 mm build volume at an accessible price. It simplifies the setup and maintenance and reduces manual operations through fully automatic bed leveling and a quick-swap nozzle. Neo is a go-to option for first-time users, students, and young creators who are new to 3D printing.

Pricing and Availability

The Ender-3 V3 Mega and Neo are now available to order through Creality's official online stores in the US and Europe. In the US, the Mega Combo is available at an early-bird price of $669 from October 15 to November 10, while the Neo Combo is available at an early-bird price of $329 during the same period. In Europe, the Mega Combo is priced at €699, with four free filament rolls included on orders placed from October 15 to November 30. The Neo Combo is priced at €329, with two free filament rolls included during the same period.

Share this article

NATICK, Mass., Oct. 15, 2026 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX), the global technology leader in industrial machine vision, will release earnings for the third quarter of 2026 on Wednesday, November 4, 2026, after market close.

The Company will host a conference call on Thursday, November 5, 2026, at 8:30 a.m. Eastern Standard Time (EST), to discuss the results.

Access to the conference call, and a replay that will be available following the call, may be found on the Cognex Investor Relations website at https://www.cognex.com/investor. The telephone number for the live call is (877) 704-4573 or (201) 389-0911 if outside the United States.

About Cognex

For over 40 years, Cognex has been making advanced machine vision easy, paving the way for manufacturing and distribution companies to become faster, smarter, and more efficient through automation. Innovative technology in our vision sensors and systems solves critical manufacturing and distribution challenges, providing unparalleled performance for industries from automotive to consumer electronics to packaged goods.

Cognex makes these tools more capable and easier to deploy thanks to a longstanding focus on AI, helping factories and warehouses improve quality and maximize efficiency without needing highly technical expertise. We are headquartered near Boston, USA, with locations in over 30 countries and more than 30,000 customers worldwide. Learn more at cognex.com.

Investor Relations Contact:

Greer Aviv

Head of Investor Relations

Cognex Corporation

[email protected]

SOURCE Cognex Corporation

Share this article

IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caterpillar Inc. (NYSE: CAT) will release third-quarter financial results at 5:30 a.m. CDT on Thursday, Oct. 29. The full text of the release will be available at investors.caterpillar.com/financials/quarterly-results and on PR Newswire. The release will be furnished to the U.S. Securities and Exchange Commission (SEC) via a Current Report on Form 8-K in compliance with applicable SEC rules.

Teleconference and webcast access:

A real-time, listen-only teleconference and webcast of the quarterly results call that Caterpillar conducts with securities analysts and institutional investors will begin at 7:30 a.m. CDT on Thursday, Oct. 29. Supporting materials will be available before the webcast at investors.caterpillar.com/events-presentations.

In addition to the webcast, the one-hour conference call can also be accessed by telephone from both domestic and international locations, with a conference ID provided below:

Conference ID:                                      6824010

Participant Toll-Free Dial-In Number:    (800) 715-9871 

Participant Toll Dial-In Number:            +1 (646) 307-1963 

The call can be accessed in real-time at investors.caterpillar.com/financials/quarterly-results. Listeners should go to the website before the live event to download and install any necessary audio software. The transcript from the conference call will be available at investors.caterpillar.com/financials/quarterly-results following the webcast.

For those unable to participate in the live broadcast, the replay will be available at investors.caterpillar.com/financials/quarterly-results shortly after the live event. There is no charge to access the webcast. A telephone replay will not be available.

About Caterpillar

For more than a century, Caterpillar has built a better, more sustainable world. With 2025 sales and revenues of $67.6 billion, Caterpillar Inc. is shaping the future as the world's leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Backed by one of the largest independent global dealer networks and financing services through Cat Financial, the company's primary business segments: Power & Energy, Construction Industries and Resource Industries are solving customers' toughest challenges through commercial excellence and advanced technology, driven by a highly skilled, dedicated global team. Learn more at www.caterpillar.com.

Caterpillar's latest financial results are also available online:

https://investors.caterpillar.com/overview/default.aspx

https://investors.caterpillar.com/financials/quarterly-results/default.aspx (live broadcast/replays of quarterly conference call)

SOURCE Caterpillar Inc.

Share this article

MIAMI, Oct. 15, 2026 /PRNewswire/ -- EID Group Safety Solutions and the Standard Fluids Corporation™ proudly announce a strategic partnership for Latin America and the Caribbean. Under this joint initiative, EID Group will serve as a Master Distributor across the region for Standard Fluids' SF 1230™ Fire Protection Fluid.

Combining Standard Fluids' industry-leading clean agent technology with EID Group's extensive regional presence, the two organizations will collaborate closely to advance regional commercialization, establish authorized distribution channels, and scale certified refill and recharge facilities across Latin America and the Caribbean.

Key priorities of the joint partnership include:

"Partnering with Standard Fluids allows us to bring a premium clean agent solution to our customers throughout Latin America and the Caribbean. Together, we are building a robust network of distributors, integrators, and service partners dedicated to protecting mission-critical assets over the full lifecycle of fire suppression systems." — Hernan Barrientos, VP of Global Sales, Distribution, & OEM Partnerships and Carlos Herrera, CEO, EID Group

"This alliance represents a powerful combination of product excellence and deep market access," added Luis Gonzalez, President & CEO of Standard Fluids. "EID Group's regional technical leadership and extensive network complement our commitment to quality. Working as unified partners, we will ensure clients across Latin America and the Caribbean receive world-class fire protection solutions paired with unmatched local support."

EID Group and Standard Fluids look forward to a successful, long-term collaboration expanding safety and clean agent access across the region.

About EID Group Safety Solutions

Founded in 2002 and headquartered in Miami, Florida, EID Group is a strategic regional platform that serves as a direct extension for international manufacturers expanding into Latin America and the Caribbean. By leveraging a network of over 200 commercial partners, the company moves beyond traditional distribution to provide integrated product supply, technical engineering support, and comprehensive market positioning. This integrated approach enables global brands to accelerate sustainable business growth and solidify their presence throughout the region. For more information, visit www.eidgroupllc.com.

About Standard Fluids Corporation

Standard Fluids Corporation™ is a US-based chemical supplier specializing in environmentally sustainable, high-performance fluorinated fluids for industries including fire protection, data center immersion cooling, semiconductor manufacturing, and aerospace and defense. Led by industry veterans behind the development and commercialization of SF 1230™ Fire Protection Fluid, Standard Fluids offers turnkey solutions, engineering consulting services, and cradle-to-cradle lifecycle management to its global customer base. For more information, visit www.standardfluids.com

Media Contacts

EID Group Safety Solutions

Hernan Barrientos, VP of Global Sales, Distribution, & OEM Partnerships

[email protected]

+1 (954) 650-4371

Standard Fluids Corporation

Conrad Kaminski, Strategic Development Manager

[email protected]

+1 (888) 322-1248

SOURCE Standard Fluids Corporation

Share this article

Reallusion's 2026 3D Character Contest - Meet the Winners!

SAN JOSE, Calif., Oct. 15, 2026 /PRNewswire/ -- Reallusion's 2026 3D Character Contest was held from June 1st to October 1st, 2026. Within 3 months, 200 submissions were submitted from 49 countries. The contest showcases the best 3D character design and animation created using Reallusion's powerful character production ecosystems: Character Creator for 3D character creation, iClone for facial and body animation, and AccuRIG for rigging.

"We at Reallusion are thrilled to watch so many world-class character artists integrate Character Creator and iClone into their professional workflows. This contest clearly demonstrated that Character Creator gives artists complete creative freedom to build original 3D characters in any style or genre. Huge congratulations to every participant. We are excited to keep pushing the boundaries of 3D innovation for the community!"

– Enoc Burgos, Reallusion Director of Partnership Marketing

Prizes Sponsored by Renowned Industry Leaders

The Contest was hosted by Reallusion and sponsored by industry leaders such as NVIDIA, Maxon, Epic Games, Unity, SideFX, Marvelous Designer, MSI, WD, and CenterGrid. Through this contest, Character Creator's extensive pipeline lets artists seamlessly integrate a new workflow for rapid creativity with zero sacrifice in character quality.

Meet Our Winners And Their Testimonials

The contest challenged artists to create stunning, original 3D characters that not only showcased their artistic abilities, but also demonstrated mastery of animation tools like Character Creator and iClone. After weeks of careful evaluation by our esteemed panel of judges, the following winners stood out for their exceptional work.

Watch winner video: https://youtu.be/zhGfrHHtT7Y

Realistic Character Design

Under this category, entrants create a realistic human character in Character Creator by combining the character base with tools like ZBrush, Substance Painter, Marvelous Designer, Blender, Wrap, Texturing.xyz, and Maya. Watch their winning entry and testimonials below.

1st Place: Jax: Soul of the Street – by Jimmy Watelle, Manager | Costa Rica

"Character Creator and the Blender Data Link helped me a lot in building the base of the Jax character, but I also faced numerous challenges related to my skill level and navigating between software, sometimes losing data or synchronization along the way. This project brought me as much enjoyment, and it helped me grow tremendously." – Jimmy Watelle

2nd Place: Shannaz – by Leudemar "Leo" Lima, Concept Artist | Brazil

"Character Creator helped me bring my design to 3D with a lot of fidelity and realism; easy to use and intuitive, CC5 is a really powerful tool for concept artists." – Leudemar "Leo" Lima

3rd Place: An Unearthly Find – by Jeet Shah, Technical Artist | India

"The speed of CC5 in making changes to primary forms for any character is impeccable and probably the best among any 3D software I've ever used. Need a skinny short girl- tweak a few sliders you get a skinny short girl. Need a fat stubby creature- tweak some more sliders and take it to ZBrush and you have a humanoid creature in under an hour all the while maintaining the subdivided geometry details in CC5 thanks to GoZ Plus. And all of them with a full-body skeleton that's ready to add some controls for posing. The new HD morphs in CC5 are certainly an upgrade to the previous version, where the lack of base mesh resolution made the morphs a bit less detailed; the new ones still come out quite detailed. One other feature I've heavily used is the new addition to Auto Setup for Maya. That allowed for a seamless experience in making the facial expressions on the characters directly in Maya, where I rendered them."– Jeet Shah

Stylized Character Design

Under this category, entrants create a stylized character in Character Creator by combining the character base with tools like ZBrush, Substance Painter, Marvelous Designer, Blender, Wrap, Texturing.xyz, and Maya. Watch their winning entry and testimonials below.

1st Place: Kohaku - Warden of Memories – by Oscar Fernandez Gonzalez, 3D Character Artist | Spain

"As a sculptor, Character Creator lets me start from a clean, optimized base mesh that I can freely customize in ZBrush. Moving back and forth between ZBrush and CC5 allows me to use each application for what it does best, making the entire workflow faster and more efficient. My favorite feature is being able to test poses on the character with incredible precision. It's fast, intuitive, and a genuinely enjoyable part of the creative process." – Oscar Fernandez Gonzalez

2nd Place: Erlen From Lemuria's Savage Lands – by Felix Enrique Yaguare Lopez, Student and Freelancer | Venezuela

"Character Creator allowed me to bring my character to life effortlessly. Being able to quickly test and iterate different poses gave me the freedom to explore Erlen in multiple situations, something that would have been impossible in my timeframe, as I joined the contest a month and a half late while finishing my class projects for Libel Academy." – Felix Enrique Yaguare Lopez

3rd Place: Alyssa – by Thivolan Moodley, 3D Sculptor & Freelancer | South Africa

"I was able to use the base mesh to really push the design from start to finish without needing to retopologize or change much else! This helped me focus on sculpting and likeness more!" – Thivolan Moodley

Realistic Character Animation

Use iClone to create a realistic animation for a character made with the CC3+ Base. The character model can be customized with Reallusion tools and content or third-party software like ZBrush, Blender, Unreal Engine. Watch their winning entry and testimonials below.

1st Place: Franco Colapino – by Off World, FCGI Cinematics Freelancer | Argentina

"Without Reallusion's tools, achieving this level of quality and ease of iteration in pursuing our goal would not have been possible; the power and creative freedom it provides are immense." – Off World

View Off World's entry and WIP

2nd Place: The Hunt – by Joseph Hoback, 3D | United States

"There's no way I could have gotten as far as I did without the use of an iClone. The mocap informed not only the timing and energy but also the character as a whole." – Joseph Hoback

3rd Place: Special ops: Lioness – by Hector Mercado, CGI artist & Filmmaker | Dominican Republic

"The new Headshot 3 features, together with the AI-assisted reference image generation and cleanup, really help in getting the character likeness when trying to create a digital double!" – Hector Mercado

Stylized Character Animation

Under this category, contestants use iClone to create a stylized animation for a character made with the CC3+ Base. The character model can be customized with Reallusion tools and content or third-party software like ZBrush, Blender, Unreal Engine. Watch their winning entry and testimonials below.

1st Place: STONE GODZ – by Dazhi Benjamin Sokomba, Animator | Nigeria

"I used iClone for the final real-time render, Character Creator 5 for the main character and AccuRIG for the stone characters." – Dazhi Benjamin Sokomba

2nd Place: Moss Fairy – by Affan Shiekh, CGI artist | Pakistan

"Character Creator 5 is amazing. It gets better every year, and I would like more implementations for the Blender addon!" – Affan Shiekh

3rd Place: Max Mad Animation – by Soorena Sardarzadeh, CGI artist & Filmmaker | United States

"With iClone, making animation isn't harder than it needs to be." – Soorena Sardarzadeh

Best AccuRIG Characters

Powered by AccuRIG, artists can transform static models into fully animatable characters, regardless of topology. The winning characters showcase high sculpting details with attractive poses and professional renders. Reallusion selected four winners from this category, and here are the winners, entries, and respective WIPs.

- Oscar Fernandez Gonzalez (Spain)

- Laura Antonacci (Italy)

- Carolyna Figueiredo (Portugal)

- Stasia Bubnova (Russian Federation)

Special Awards

Special Awards recognize outstanding achievement across specific technical and artistic categories. Beyond their distinctive visual aesthetics, these winning entries demonstrate a deep mastery of 3D pipelines and creative problem-solving techniques. Their entries present compelling character designs, solid anatomy, and exceptional composition. View all winning entries and WIPs.

- Vanesa Arambašić (Croatia)

- Jacopo Filo della Torre (Italy)

- Bahar Tavakoli (Iran)

- David Sujono (Australia)

- Olivier Beguin (Switzerland)

- Ignacio Coronel (Argentina)

- Joachim Jensen (Denmark)

- Jorge Leonardo Ayala Arias (Colombia)

- Sangkoo Lee (Republic of Korea)

- Mobin Hivehchi (Iran)

- Frederick Talavera Martinez (Spain)

- Carlos Humberto Rivas Garcia (Venezuela)

- Eva Sophie Cringle (Belgium)

- Myron Mortakis (United States)

- Massimo De Antonis (Italy)

- Saillish (Australia)

- Weedi Masindraoka (Madagascar)

- Sadegh Khavand (Iran)

- Rafael S. Benedicto (Philippines)

- Angel Ricalde (Peru)

Honorable Mentions

Honorable Mentions celebrate standout entries that captivated the judging panel through exceptional dedication, skill, and creative vision. While not taking home a top placement, these artists delivered remarkable craft and passion throughout the competition. View all Honorable Mention entries and WIPs.

- Ariya Hasani (Iran)

- Markus Haertel (Brazil)

- Kurt Boutilier (Canada)

- Onur Erdurak (Turkey)

The judging process for the "2026 Reallusion 3D Character Contest" proved to be quite difficult and took many hours of deliberation. In addition to the top 3 placements in Best Character Animation & Best Character Design, Reallusion also selected 28 winners for AccuRIG characters, Special Awards, and Honorable Mentions. See the Winner Page for winner details and showcases, and we look forward to your entry submission next year!

SOURCE Reallusion Inc.

Share this article

Alliance aims to accelerate digital transformation for contracting and supplier management across global enterprises

NEW YORK and LEHI, UTAH, Oct. 15, 2026 /PRNewswire/ -- Deloitte Tax LLP ("Deloitte") and Sirion today announced a strategic US alliance to help organizations transform how they manage contract obligations and supplier relationships across the enterprise. The alliance combines Deloitte's Legal Business Services (LBS) transformation experience with Sirion's advanced, AI-powered Contract Lifecycle Management (CLM) platform to streamline contracting processes, enhance visibility into contractual performance and help enable greater value for enterprises embarking on contracting technology transformations.

Deloitte and Sirion are expanding their collaboration on integrated AI-powered solutions that provide deeper visibility into commercial terms, supplier relationship data and contractual compliance across complex global supply chains. The alliance may also help connect contract data with broader enterprise systems including procurement, finance and enterprise resource planning (ERP) platforms. These capabilities are increasingly critical for a global organization's digital core as CLM becomes a core consideration in ERP transformation projects.

"As organizations accelerate their digital transformation journeys, the ability to manage contracts intelligently has become a strategic imperative, not just for legal teams, but for tax, finance, procurement and the broader enterprise," said Carin Giuliante, chair and CEO, Deloitte Tax LLP. "By combining Deloitte's deep experience in legal business services with Sirion's AI-powered platform, we're helping organizations unlock new levels of transparency, automation and control across their global operations. This alliance is about reimagining contract management as a driver of business value, insight, and risk mitigation in an increasingly complex world."

"Sirion's AI-first platform was built to handle the complexity of global supply chains and financial relationships," said Ajay Agrawal, CEO, Sirion. "Our alliance with Deloitte may help organizations harness the power of AI to promote contract compliance, enhance supplier performance and assist broader technology transformations, including ERP initiatives."

"Contract lifecycle management is rapidly evolving from a back-office function to a strategic enabler of business transformation," said Mark Ross, US Sirion alliance leader and Legal Business Services growth and markets leader, Deloitte Tax LLP. "By deepening our collaboration with Sirion, we are helping empower clients to unlock the full potential of their contract data, streamline supplier and customer relationships and drive measurable outcomes across tax, legal and finance functions."

The alliance underscores Deloitte and Sirion's shared dedication to advancing AI-enabled legal technology as demand for CLM solutions continues to grow.

About Sirion

Sirion is a leading AI-native contract lifecycle management platform that helps enterprises store, create, and manage contracts with greater intelligence and control. By combining a conversational interface with specialized AI agents, Sirion enables organizations to manage contractual risk, improve compliance, and gain deeper insight across millions of contracts. Sirion supports more than seven million contracts across over 100 languages for many of the world's largest enterprises. For more information, visit www.sirion.ai.

About Deloitte

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 9,000 US-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters for our people, clients, and communities. We bring together distinct talents, technologies, disciplines, and an ecosystem of alliances to help tackle today's most complex business challenges and drive long-term progress. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 180 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's approximately 500,000 people worldwide connect for impact at www.deloitte.com.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Deloitte Legal means the legal practices of DTTL member firms, their affiliates or their related entities that provide legal services. The exact nature of these relationships and provision of legal services differs by jurisdiction, to allow compliance with local laws and professional regulations. Each Deloitte Legal practice is legally separate and independent and cannot obligate any other Deloitte Legal practice. Each Deloitte Legal practice is liable only for its own acts and omissions, and not those of other Deloitte Legal practices. For legal, regulatory and other reasons, not all member firms, their affiliates or their related entities provide legal services or are associated with Deloitte Legal practices.

SOURCE Deloitte

Share this article

MacPaw launches Eney, the proactive AI assistant that lives on your Mac and iPhone and handles everyday tasks

Eney understands what is happening across your apps, files and system, prepares the next step, and asks before it acts.

BOSTON, Oct. 15, 2026 /PRNewswire/ -- MacPaw, a global AI technology company, today launched Eney, a proactive AI assistant that lives on Mac and iPhone. Unlike other AI assistants, Eney is built for the Mac: it understands the context of the machine itself — the apps you work across, the files on your disk, the meetings on your calendar — and spots what needs attention before you do. A call about to start. A meeting that needs a summary. A disk running out of space. Eney notices, prepares the next step, and puts it in front of you for approval, without the need to switch between multiple apps, tools and products.

MacPaw sees Eney becoming the universal interface for how you work on your Mac — one place where everything connects, tasks get done, and work keeps moving forward.

Eney is built for anyone on Mac and iPhone whose day fills up with work that shouldn't take this long — chasing a document, catching up on threads, prepping for a call that starts in an hour. Freelancers, assistants, managers, busy people carrying too much in their heads. It handles the tasks, with less for you to remember and chase. No complicated setup or AI know-how. Just ask and skip to done.

Eney arrives in a year defined by AI agents that act on their own. Adoption isn't the problem — trust is. In MacPaw's own research, 81% of US Mac users had used an AI tool in the previous three months, but only 39% said AI was embedded in how they work. Eney is built for that gap: proactive, never autonomous. By default, Eney asks before it sends a message, changes an event or moves a file — and you decide how much it can do on its own. (MacPaw research, US Mac users, July–August 2026.)

"Since 2008, MacPaw has built tools that take care of the Mac. Eney takes the next step: not a chatbot, but a careful colleague — an assistant that lives on your Mac and iPhone and takes care of the work you do on them. It spots what's waiting, prepares the next step, and asks before anything is sent or changed," said Oleksandr Kosovan, Founder and CEO of MacPaw.

Built on MacPaw's own AI stack

Eney is the first product to be powered by MacPaw's own AI stack — AI technology the company builds and owns as it evolves its standalone products into a connected ecosystem. At its core is Mnemos, MacPaw's memory layer for AI. Eney remembers what matters to you, updates a fact when you correct it or it goes out of date, and shows you when an answer draws on something it remembered. Mnemos manages only Eney's own memory: it never reads or changes your files or other apps.

How Eney works

Eney lives on your Mac, not in a browser tab. So the assistant that drafts your reply can also tell you what's filling up your disk. For example, Eney can recognize an upcoming meeting on your calendar and remind you before it starts. When the call begins, it can offer to transcribe the conversation, then prepare meeting notes, action items and a follow-up invitation for your approval. What would normally require moving between several apps can be handled through one assistant.

- Help before you ask. Copy something and Eney offers the next step: a summary, a currency or time-zone conversion, a translation. It reminds you before calls, too.

- Your apps, connected in one place. Eney works with Apple Mail, Calendar and Reminders out of the box, and connects to Gmail, Google Calendar, Google Drive, Slack, Notion, Jira, Linear and more. New connectors are added regularly.

- Meeting notes, no bot in the call. When a call starts in any app, Eney offers to transcribe it and write up the notes. Afterward, it drafts the tasks, the recap and the next invite, ready for you to send.

- Eney Wand. Press Option-W, drag over anything on screen, and Eney offers what to do with it: translate text in place, convert a price, turn a date into a calendar event, copy the text out of an image, or blur what shouldn't be shared. No screenshots to save, no switching apps.

- Ready-made workflows. Morning Brief, Plan My Day, Weekly Review and more, run on demand or on a schedule. Setup takes a few simple clicks, with no technical configuration.

- Mac care, built in. Eney warns about low disk space, memory pressure and apps that keep crashing, and suggests a fix. It keeps Downloads tidy and finds any file in seconds. Nothing moves until you confirm — the kind of care MacPaw has built since 2008.

- Writing checked where you write. Eney Spell fixes spelling, grammar and wording right in Mail, Slack, Notes or the browser.

- Talk or type. Double-tap Option to open Eney from anywhere, then type text or speak to it. Eney works in eight languages, including English, German, Spanish, French, Italian, Polish, Brazilian Portuguese and Ukrainian.

People talk to it naturally, without complicated prompts, technical language or workflow-building knowledge — one instruction can turn into a completed task.

Get started with Eney

Eney by MacPaw is available now for Mac at the website eney.ai and is free to try for your first 14 days with 10,000 AI credits. Eney is also available for iPhone on the App Store.

Users can also sign in with a Setapp account (Setapp membership isn't required). It needs macOS 15 or later, and Setapp AI credits (credits show as Setapp AI credits in Settings > Usage).

About MacPaw

MacPaw is a global AI technology company founded in Kyiv, Ukraine, with offices in Boston, MA and across the EU, building an ecosystem of software, services, and AI-powered experiences for people who live on Mac. Designed around a deep understanding of Mac users, MacPaw creates thoughtful technology that helps users and developers get more from their devices and workflows.

Media contact : [email protected]

SOURCE MacPaw

Share this article

FAUQUIER COUNTY, Va., Oct. 15, 2026 /PRNewswire/ -- Virginia Cancer Specialists, the Commonwealth's leading cancer care practice, is proud to announce the grand opening of its newly relocated, expanded Fauquier location in Warrenton, VA, on November 9, 2026. The modern facility enhances access to comprehensive cancer care for patients and families throughout Fauquier County and the surrounding region while laying the foundation for future growth in clinical research and innovative treatment options.

The expanded office reflects Virginia Cancer Specialists' longstanding commitment to delivering world-class cancer care close to home. Patients will continue to receive care from the same trusted physicians and care team they know, now in a larger, enhanced environment designed to support a seamless, compassionate patient experience.

As Virginia's premier community oncology practice, Virginia Cancer Specialists provides integrated cancer care under one roof, including medical oncology, hematology, supportive services, care coordination, patient navigation, and access to the latest treatment advances. The expanded Fauquier location will strengthen the practice's ability to meet growing demand while ensuring patients can receive exceptional care without traveling far from family, work, and support systems.

"This expansion represents our commitment to the communities we serve and our vision for the future of cancer care," said Ann Miner, Executive Director of Virginia Cancer Specialists. "The growth behind our relocated Fauquier location has only been possible because of the trust our patients place in us, the dedication of our physicians and staff, and the ongoing support of the community. By expanding our footprint today, we are creating opportunities to bring even more advanced services, clinical expertise, and research opportunities to patients in the years ahead."

Looking toward the future, the Fauquier location is expected to become an important hub for clinical research and innovation. As Virginia Cancer Specialists continues to expand its nationally recognized research program, starting in 2027, the site is positioned to support broader participation in clinical trials and provide local patients with access to emerging therapies and innovative treatment options.

"Our mission has always been to provide patients with the highest quality cancer care in the communities where they live," said Jey A. Maran, MD, Practice President of Virginia Cancer Specialists, who sees patients in the Bristow and Fauquier locations. "This expanded facility allows us to better serve patients today while preparing for tomorrow's innovations. We are excited about the opportunities ahead, including expanding access to clinical research and continuing to bring leading-edge treatments to our community."

The new Fauquier office, located at 410 Rosedale Court, Suite 270, Warrenton, VA, 20186, reflects Virginia Cancer Specialists' continued investment in community-based oncology care and reinforces its reputation as Virginia's #1 cancer practice, as ranked by Castle Connolly, whose Top Doctors represent the top 7% of all US practicing physicians. By combining expert physicians, advanced therapies, comprehensive support services, and a commitment to research, Virginia Cancer Specialists remains focused on delivering the best possible outcomes for patients and families facing cancer.

About Virginia Cancer Specialists

Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia, has been recognized as the #1 physician practice in Virginia in cancer care and across all medical specialties for 3 years running (2024-2026), as recognized by Castle Connolly Top Doctors. It features a world-class treatment team offering access to the most current treatment protocols fighting cancer and blood diseases. It's also home to the Virginia Cancer Specialists Research Institute and the largest clinical trials portfolio in the Mid-Atlantic – including a dedicated research facility for Phase I clinical trials and later-stage trials through a joint venture with Fairfax's NEXT Oncology. The practice offers medical oncology, radiation oncology, musculoskeletal tumor surgery, breast surgery, thoracic surgery, genetic counseling, support cancer care, financial counseling, onsite laboratory and pharmacy, language services, telehealth, nurse advice line, and much more. Virginia Cancer Specialists is part of The US Oncology Network. This collaboration unites the practice with more than 600 sites of care across 31 states, 2,700 affiliated physicians, and research and data from thousands of patients with cancer in clinical trials across the country. Its 2024 partnership with the renowned Sara Cannon Research Institute opens the door to hundreds of additional clinical studies, increases care to more patients, and has played a role in more than 100 FDA-approved cancer therapies. For more information about The US Oncology Network, which is supported by McKesson, a trusted name and global leader in healthcare for over 180 years, visit USOncology.com. For more information about Virginia Cancer Specialists, visit: VirginiaCancerSpecialists.com

Media Contact

Jean Dzierzak

[email protected]

703-963-5770

SOURCE Virginia Cancer Specialists

Share this article